“Global Protein Expression market set to grow to $3.2bn by 2024” says Visiongain report

24 October 2019
Pharma

Visiongain has launched a new pharma report Global Protein Expression Market Report: Cell-free Expression System, Prokaryotic/Bacterial Expression System, Yeast Cell Expression Systems, Algal-based Expression Systems, Insect Cell Expression Systems, Mammalian Cell Expression Systems, Reagents, Expression Vectors, Competent Cells, Instruments, Services, Therapeutic Applications, Industrial Application, Research Application, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs).

The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.

The lead analyst of the report commented "Recombinant proteins will continue to be essential reagents for drug discovery projects in the future and that technological developments will emerge to match changes in demand or to keep in step with advances in other application areas. Another great opportunity for future growth in the protein expression market is provided by emerging countries, especially China and India. Their markets are growing at a faster rate than that of the developed Western markets.

The demand for expertise in recombinant protein expression development is another opportunity for the market, and this will allow smaller niche companies to compete with the large multinational CROs, resulting in more companies entering the market and more products and services being offered."

Leading companies featured in the report include Agilent Technologies, Bio-Rad Technologies, EMD Milipore, New England Biolabs, Inc., Oxford Expression Technologies, Ltd., Promega Corporation, Qiagen NV, Takara Bio, Inc., Thermo Fisher Scientific, Inc. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever